entertainment -WSS

entertainment

author：Wikipedia 2025-10-02 09:47:07 - browse：325

Illustration of researchers working among oversized pill bottles, lab equipment, and medicine for story about the development of obesity medications – health and pharma coverage from STAT — Molly Ferguson for STAT

The exploding popularity of drugs like Wegovy and Mounjaro has propelled dozens of companies to develop their own obesity treatments, with most of them trying to emulate the same approach as the blockbuster products.

Nearly 70 obesity treatments are in development, and about two-thirds use a similar mechanism as Wegovy and Mounjaro, according to the STAT Obesity Drug Tracker, a new database compiled by STAT. There are also a minority of companies pursuing entirely different approaches, hoping that they will stand out among the field.

The tracker, which will be updated with significant developments each quarter, gives a sense of what new mechanisms could hit the market, how they would be delivered, and which companies are running the most trials.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Supreme Court strikes down use of affirmative action
Next article： Driven by the pandemic, applicants flood public health schools

focus

WSS

I learned firsthand about improving diversity in clinical trials

Why Congress must ban federal programs from using QALYs

Why Congress must ban federal programs from using QALYs

Massive project maps cells in human brain in unprecedented detail

DeSantis talks Trump, trans issues and 'what wokeness is'

Wife of Gilgo Beach murder suspect files for divorce, court filing shows

knowledge

entertainment

leisure time

Trump demands the U.S. pay no more for drugs than other countries … again

Awakening the world to the whoosh: A patient's crusade

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

European regulators consider appeal over Amylyx ALS drug

Malaria cases in Florida and Texas: Here’s what you need to know

Takeaways from AdvaMed, the largest medical devices conference

Trump demands the U.S. pay no more for drugs than other countries … again

What's changing in Medicare's open enrollment this year?

How one medical school became remarkably diverse

Driven by the pandemic, applicants flood public health schools

hotspot

Winning ticket for $1 billion Powerball jackpot sold in California

How doctors and nurses shape Google's AI

Life sciences deals on track to hit lowest point since 2017

How should state employee insurance handle Wegovy?

European regulators recommend Amylyx's ALS drug be rejected

Akero's treatment for NASH falls short in cirrhosis study

hotspot

focus

entertainment

hotspot